A newly published case report out of Germany has given us something incredibly meaningful: human evidence that the defining genetic fusion in Ewing sarcoma can be targeted with a vaccine—and the immune system can learn to recognize it.

At Little Warrior Foundation, we think about the entire path to the patient. That’s why we’re making bigger investments, like the $2.5 million we’ve committed to the upcoming vaccine trial. Translational medicine takes time — frustratingly so —but we have faith that these are necessary steps to avoid the Valley of Death.